Sugi Predict

Sugi Predict / Compounds / SCHEMBL2954334

SCHEMBL2954334

SCHEMBL2954334

O=C(O)c1cc2c(s1)CCC2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DAO P14920 1/20 1.00
▸ ALDH1A1 P00352 12/20 0.92
▸ POLB P06746 5/20 0.57
▸ KMT2A Q03164 4/20 0.57
▸ CYP1A2 P05177 3/20 0.57
▸ CYP2C19 P33261 3/20 0.57
▸ MEN1 O00255 3/20 0.57
▸ PKM P14618 1/20 0.57
▸ CYP3A4 P08684 1/20 0.57
▸ GAA P10253 1/20 0.57
▸ CYP2C9 P11712 1/20 0.57
▸ HPGD P15428 4/20 0.56
▸ TP53 P04637 2/20 0.56
▸ MAPK1 P28482 1/20 0.56
▸ RAB9A P51151 4/20 0.54
▸ SMN1; SMN2 Q16637 3/20 0.54
▸ TDP1 Q9NUW8 2/20 0.52
▸ NR4A1 P22736 1/20 0.52
▸ RECQL P46063 1/20 0.52
▸ BLM P54132 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1068704 0.96 ALDH1A1 (1.00) DAOALDH1A1POLBKMT2ACYP1A2
SCHEMBL28870929 0.94 ALDH1A1 (0.96) DAOALDH1A1POLBKMT2ACYP1A2
SCHEMBL28870926 0.94 ALDH1A1 (0.96) DAOALDH1A1POLBKMT2ACYP1A2
SCHEMBL3743711 0.94 ALDH1A1 (0.96) DAOALDH1A1POLBKMT2ACYP1A2
SCHEMBL2462740 0.82 DAO (0.70) DAOALDH1A1POLBKMT2ACYP1A2
SCHEMBL3096138 0.82 DAO (0.70) DAOALDH1A1POLBKMT2ACYP1A2
SCHEMBL15407033 0.82 DAO (0.69) DAOALDH1A1POLBKMT2ACYP1A2
SCHEMBL3918053 0.81 ALDH1A1 (0.73) DAOALDH1A1POLBKMT2ACYP1A2
SCHEMBL11174836 0.79 ALDH1A1 (0.66) DAOALDH1A1POLBKMT2ACYP1A2
SCHEMBL6424933 0.79 ALDH1A1 (0.65) DAOALDH1A1POLBKMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1863766-B1 CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF GILEAD CONNECTICUT INC (US) 2015-05-20 — — EP claimed
EP-1863766-A2 CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF CGI Pharmaceuticals, Inc. (US) 2007-12-12 — — EP claimed
US-20060229337-A1 Certain substituted amides, method of making, and method of use thereof GILEAD CONNECTICUT, INC. 2006-10-12 — — US claimed
WO-2006099075-A2 CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF CGI PHARMACEUTICALS, INC. (US) 2006-09-21 — — WO claimed
EP-4640806-A1 WATER-SOLUBLE AUTOMATIC DISHWASHING DETERGENT POUCH The Procter & Gamble Company (US) 2025-10-29 — — EP disclosed
US-20250326994-A1 WATER-SOLUBLE AUTOMATIC DISHWASHING DETERGENT POUCH PROCTER & GAMBLE (US) 2025-10-23 — — US disclosed
EP-4626871-A1 CD93 INHIBITORS Universität Bern (CH) 2025-10-08 — — EP disclosed
US-12383560-B2 Compounds and uses thereof FOGHORN THERAPEUTICS INC. (US) 2025-08-12 — — US disclosed
WO-2025097104-A1 THIENYL COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER PGI DRUG DISCOVERY LLC (US) 2025-05-08 — — WO disclosed
WO-2024115637-A1 CD93 INHIBITORS Universität Bern (CH) 2024-06-06 — — WO disclosed
EP-4378932-A1 NOVEL CD93 INHIBITORS Universität Bern (CH) 2024-06-05 — — EP disclosed
US-11807641-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2023-11-07 — — US disclosed
WO-2007030761-A2 ACYCLIC 1,4-DIAMINES AND USES THEREOF SMITHKLINE BEECHAM CORPORATION (US) 2007-03-15 — — WO disclosed
US-20060229337-A1 Certain substituted amides, method of making, and method of use thereof GILEAD CONNECTICUT, INC. 2006-10-12 — — US disclosed
WO-2006099075-A2 CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF CGI PHARMACEUTICALS, INC. (US) 2006-09-21 — — WO disclosed
WO-2006089100-A1 BENZOXAZOLE CARBOXAMIDES FOR TREATING CINV AND IBS-D AMR TECHNOLOGY, INC. (US) 2006-08-24 — — WO disclosed
US-20060183769-A1 Benzoxazole carboxamides for treating CINV and IBS-D AMR TECHNOLOGY, INC. (US) 2006-08-17 — — US disclosed
WO-2006029210-A2 ACYCLIC 1,3-DIAMINES AND USES THEREFOR SMITHKLINE BEECHAM CORPORATION (US) 2006-03-16 — — WO disclosed
US-5304657-A Insecticides ISHIHARA SANGYO KAISHA LTD. (JP) 1994-04-19 — — US disclosed
EP-0483647-A1 Hydrazine compounds or their salts, processes for producing them and pesticides containing them ISHIHARA SANGYO KAISHA, LTD. (JP) 1992-05-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11807641-B2 MASP-2 inhibitors and methods of use MASP2, METAP2, SPINT2 DAO 3003/4885ALDH1A1 4709/4885POLB 2216/4885
US-20060183769-A1 Benzoxazole carboxamides for treating CINV and IBS-D HTR3E, BRS3, HTR3A DAO 1106/4885ALDH1A1 3208/4885POLB 3066/4885
US-12383560-B2 Compounds and uses thereof VHL, CLN6, TFEB DAO 4261/4885ALDH1A1 2571/4885POLB 165/4885
US-20060229337-A1 Certain substituted amides, method of making, and method of use thereof BTK, SYK, MYD88 DAO 1611/4885ALDH1A1 3686/4885POLB 3872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.